Regeneron Pharmaceuticals, Inc. (REGN)

FairStock Score: 66/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the 2026-10-26 close of $807.67, Regeneron is a high-quality but not cheaply priced biotech. The business is profitable: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $4.3B, net income $1.3B, and diluted EPS $12.23; that compares with fiscal Q2 2025 revenue $3.7B, net income $1.4B, and diluted EPS $12.81, so sales rose but profit slipped. The latest quarter's 30.23% margin supports business quality. On an annual basis, fiscal 2025 revenue was $14.3B versus $14.2B in fiscal 2024, net income $4.5B versus $4.4B, and diluted EPS $41.48 versus $38.34. The balance sheet looks sound: FairStock's data show D/E 0.09, Altman Z 6.96, Piotroski 7/9, ROE 14.04%, and ROCE 6.53%. Free cash flow was $3.6B, a 4.2% FCF yield. I see a durable franchise, an unquantified but real moat in medicines, though the computed Lynch category is SLOW GROWER: profit 5.1% a year over five years, revenue 11.0%. Valuation is the rub. FairStock's P/E is 19.98 and P/B 2.56 at the close, while the Graham Number is $528.79, leaving the price 52.24% above that conservative anchor. FairStock Score 61/100 suggests decent quality, not a bargain. I would want more consistent profit growth and a wider margin of safety before calling it compelling.

In plain English: Regeneron makes medicines for eye, immune, cancer and rare diseases. The company is profitable and carries little debt, but profit slipped in the latest filed quarter and sales growth has been modest. Based on the numbers given, the stock price looks expensive compared with one conservative value check, so it is not obviously cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer